The administration of gammaglobulin as replacement therapy to boost immune function in patients with immunodeficiency secondary to malignancy is traditionally given in the IV formulation. A pilot program at a large Canadian cancer center led by an advanced practice nurse (APN) demonstrated that transitioning patients to home-based, self-administered subcutaneous infusions (subcutaneous immunoglobulin [SCIG]) led to savings and benefits for patients and the institution. The implementation of SCIG in oncology by an APN is a novel and innovative patient-centered approach to supportive care.
At a Glance
- Replacement therapy of gammaglobulin may be safely administered via slow subcutaneous infusions in the home setting.
- Transitioning patients from IV gammaglobulin to SCIG promotes patient engagement, independence, and autonomy.
- Development, implementation, and evaluation of an SCIG program represents one role an APN can play in oncology clinical care.